<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Budesonide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01222</strong>&#160; (APRD00442)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Budesonide is a glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis. [PubChem] The extended release oral tablet, marketed as Uceris, was <span class="caps">FDA</span> approved on January 14, 2013 for the management of ulcerative colitis. Budesonide is provided as a mixture of two epimers (22R and 22S). Interestingly, the 22R form is two times more active than the 22S epimer. The two forms do not interconvert.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01222/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01222/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01222.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01222.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01222.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01222.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01222.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01222">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Bidien</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Budeson</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Budicort</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>ENTOCORT</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Entocort EC</td><td>AstraZeneca</td></tr><tr><td>Noex</td><td>Eurofarma</td></tr><tr><td>Pulmicort</td><td>AstraZeneca</td></tr><tr><td>Rhinocort</td><td>AstraZeneca</td></tr><tr><td>Rhinosol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Spirocort</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Uceris </td><td>Santarus </td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Symbicort</td><td>Budesonide + Formoterol Fumarate Dihydrate</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/corticosteroids">Corticosteroids</a></li></ul></td></tr><tr><th>CAS number</th><td>51333-22-3</td></tr><tr><th>Weight</th><td>Average: 430.5339<br>Monoisotopic: 430.23553882</td></tr><tr><th>Chemical Formula</th><td>C<sub>25</sub>H<sub>34</sub>O<sub>6</sub></td></tr><tr><th>InChI Key</th><td>VOVIALXJUBGFJZ-KWVAZRHASA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Gluco/mineralocorticoids, Progestogins and Derivatives</td></tr><tr><th>Direct parent</th><td>Gluco/mineralocorticoids, Progestogins and Derivatives</td></tr><tr><th>Alternative parents</th><td>Ketosteroids; Hydroxysteroids; Cyclohexanols; 1,3-Dioxolanes; Cyclic Alcohols and Derivatives; Ketones; Enolates; Polyamines; Acetals; Primary Alcohols; Aldehydes</td></tr><tr><th>Substituents</th><td>20-keto-steroid; 11-hydroxy-steroid; 3-keto-steroid; cyclohexanol; meta-dioxolane; cyclic alcohol; ketone; secondary alcohol; primary alcohol; enolate; ether; polyamine; acetal; carbonyl group; aldehyde; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the gluco/mineralocorticoids, progestogins and derivatives. These are steroids whose structure is based on an hydroxylated prostane moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>The oral capsule is used for the treatment of mild to moderate active Crohn's disease. The oral tablet is used for induction of remission in patients with active, mild to moderate ulcerative colitis. The oral inhalation formulation is used for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis.</td></tr><tr><th>Pharmacodynamics</th><td>Budesonide has a high glucocorticoid effect and a weak mineralocorticoid effect. It binds to the glucocorticoid receptor with a higher binding affinity than cortisol and prednisolone. When budesonide is systemically administered, suppression of endogenous cortisol concentrations and an impairment of the hypothalamus-pituitary-adrenal (HPA) axis function has been observed. Furthermore, a decrease in airway reactivity to histamine and other entities has been observed with the inhaled formulation. Generally, the inhaled formulation has a rapid onset action and improvement in asthma control can occur within 24 hours of initiation of treatment. </td></tr><tr><th>Mechanism of action</th><td>Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. The precise mechanism of corticosteroid actions on inflammation in asthma, Crohn's disease, or ulcerative colitis is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory activities against multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic and non-allergic-mediated inflammation. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in the aforementioned diseases. Because budesonide undergoes significant first-pass elimination, the both oral preparations are formulated as an extended release tablet. As a result, budesonide release is delyaed until exposure to a pH &#8805; 7 in the small intestine. </td></tr><tr><th>Absorption</th><td>Absorption is complete following oral administration. The pharmacokinetic parameters of the inhaled powder formulation are as follows: 
Tmax = 30 minutes; 
Absolute systemic availability = 39%.
When a single oral administration of 9 mg of Uceris are given, the pharmacokinetic parameters are as follows:
Tmax = 13.3 &#177; 5.9 hours;
Cmax = 1.35 &#177; 0.96 ng/mL;
AUC = 16.43 &#177; 10.52 ng&#183;hr/mL.
It is important to note that the parameters have a high degree of variability. 
When a single oral administration of Entocort EC are given, the pharmacokinetic parameters are as follows:
Tmax = 3- 600 minutes; 
Cmax = 5 nmol/L;
AUC = 30 nmol&#8226;hr/L. 
</td></tr><tr><th>Volume of distribution</th><td><p>Tablet and capsule, healthy subjects and patients = 2.2 &#8211; 3.9 L/kg;<br>
Powder, metered = 3 L/kg</p></td></tr><tr><th>Protein binding</th><td>85-90% protein bound. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Following absorption, budesonide is subject to high first pass metabolism (80-90%). Budesonide is rapidly and extensively biotransformed, mainly by CYP3A4, to its 2 major metabolites, 6b-hydroxybudesonide and 16a- hydroxyprednisolone. The glucocorticoid activity of these metabolites is negligible (</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Budesonide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00353">16-alpha-hydroxyprednisolone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/355">Details</a></td></tr><tr><td>Budesonide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00476">6-beta-hydroxybudesonide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/485">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Budesonide is excreted in urine and feces in the form of metabolites. Approximately 60% of an intravenous radiolabelled dose was recovered in the urine. No unchanged budesonide was detected in the urine.</td></tr><tr><th>Half life</th><td>Following IV administration of budesonide, the elimination half-life is 2.0 to 3.6 hours. This value does not differ between healthy adults and patients with Crohn&#8217;s disease. </td></tr><tr><th>Clearance</th><td><p>Plasma clearance, tablet = 0.9 &#8211; 1.8 L/min;<br>
Systemic clearance, powder, 22R = 1.4 L/min;<br>
Systemic clearance, powder, 22S = 1.0 L/min;<br>
0.5 L/min [Athmatic children 4 to 6 years of age]</p></td></tr><tr><th>Toxicity</th><td>Single oral doses of 200 and 400 mg/kg were lethal in female and male mice, respectively. The signs of acute toxicity were decreased motor activity, piloerection and generalized edema.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>T-box transcription factor TBX21<br>Gene symbol: TBX21<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q9UL17" target="_blank">Q9UL17 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2240017" target="_blank">rs2240017 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C Allele</td><td>Improved response for long-term asthma treatment</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/15604153" target="_blank" title="Tantisira KG, Hwang ES, Raby BA, Silverman ES, Lake SL, Richter BG, Peng SL, Drazen JM, Glimcher LH, Weiss ST: TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18099-104. Epub 2004 Dec 16.">15604153 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>T-box transcription factor TBX21<br>Gene symbol: TBX21<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q9UL17" target="_blank">Q9UL17 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2240017" target="_blank">rs2240017 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>CG allele (heterozygotes)</td><td>Better response to drug treatment (for asthma) than  rs2240017(G;G) homozygotes.</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/15604153" target="_blank" title='# Tantisira KG, Hwang ES, Raby BA, Silverman ES, Lake SL, Richter BG, Peng SL, Drazen JM, Glimcher LH, Weiss ST: TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18099-104. Epub 2004 Dec 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15604153'>15604153 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9872</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9533</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6097</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.804</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5881</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5911</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7867</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8488</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7337</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9075</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9441</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.939</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.796</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8886</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9117
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9466
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9759
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1601 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9483
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5627
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Astrazeneca lp</li>
<li>Astrazeneca pharmaceuticals lp</li>
<li>Apotex inc</li>
<li>Teva parenteral medicines inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.3m.com">3M Health Care</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Astra Pharma Inc.</li>
<li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.galderma.com">Galderma Laboratories</a></li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prometheuslabs.com">Prometheus Laboratories Inc.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Aerosol, metered</td><td>Respiratory (inhalation)</td><td>90 mcg/ACT; 180 mcg/ACT</td></tr><tr><td>Capsule, extended release</td><td>Oral</td><td>3 mg</td></tr><tr><td>Powder, metered</td><td>Respiratory (inhalation)</td><td>200 ug</td></tr><tr><td>Spray, metered</td><td>Nasal</td><td>32 ug</td></tr><tr><td>Suspension</td><td>Respiratory (inhalation)</td><td>0.25 mg/2 mL; 0.5 mg/2 mL; 1 mg/2 mL </td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>9 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Budesonide micronized powder</td><td>346.5USD</td><td>g</td></tr><tr><td>DesOwen Lot w/Cetaphil Cream 0.05% Kit Box</td><td>255.84USD</td><td>box</td></tr><tr><td>Desowen 0.05% ointment kit</td><td>217.2USD</td><td>kit</td></tr><tr><td>Desowen 0.05% cream kit</td><td>212.4USD</td><td>kit</td></tr><tr><td>DesOwen 0.05% Lotion 118ml Bottle</td><td>183.17USD</td><td>bottle</td></tr><tr><td>Pulmicort Flexhaler 180 mcg/act Aerosol Inhaler</td><td>163.34USD</td><td>inhaler</td></tr><tr><td>Pulmicort 180 mcg flexhaler</td><td>157.06USD</td><td>inhaler</td></tr><tr><td>DesOwen 0.05% Lotion 59ml Bottle</td><td>123.38USD</td><td>bottle</td></tr><tr><td>Pulmicort Flexhaler 90 mcg/act Aerosol Inhaler</td><td>121.98USD</td><td>inhaler</td></tr><tr><td>Pulmicort 90 mcg flexhaler</td><td>117.29USD</td><td>inhaler</td></tr><tr><td>Rhinocort Aqua 32 mcg/act 8.6 gm Bottle</td><td>111.96USD</td><td>bottle</td></tr><tr><td>Rhinocort aqua nasal spray</td><td>13.93USD</td><td>g</td></tr><tr><td>Entocort EC 3 mg 24 Hour Capsule</td><td>13.86USD</td><td>capsule</td></tr><tr><td>Entocort ec 3 mg capsule</td><td>12.22USD</td><td>capsule</td></tr><tr><td>Budesonide 0.5 mg/2ml Suspension 2ml Plastic Container</td><td>9.73USD</td><td>plastic</td></tr><tr><td>Pulmicort 0.5 mg/2ml Suspension 2ml Plastic Container</td><td>9.24USD</td><td>plastic</td></tr><tr><td>Budesonide 0.25 mg/2ml Suspension 2ml Plastic Container</td><td>9.07USD</td><td>plastic</td></tr><tr><td>Entocort (115 Ml) 2.3 mg/enm Enema</td><td>8.93USD</td><td>enema</td></tr><tr><td>Pulmicort 1 mg/2 ml respule</td><td>8.89USD</td><td>ml</td></tr><tr><td>Pulmicort 0.25 mg/2ml Suspension 2ml Plastic Container</td><td>7.85USD</td><td>plastic</td></tr><tr><td>Pulmicort 0.5 mg/2 ml respule</td><td>4.45USD</td><td>ml</td></tr><tr><td>Pulmicort 0.25 mg/2 ml respul</td><td>3.78USD</td><td>ml</td></tr><tr><td>Desowen 0.05% cream</td><td>2.43USD</td><td>g</td></tr><tr><td>Pulmicort Nebuamp 0.5 mg/ml Suspension</td><td>0.93USD</td><td>ml</td></tr><tr><td>Pulmicort Turbuhaler 400 mcg/dose Metered Inhalation Powder</td><td>0.62USD</td><td>dose</td></tr><tr><td>Pulmicort Nebuamp 0.25 mg/ml Suspension</td><td>0.46USD</td><td>ml</td></tr><tr><td>Pulmicort Turbuhaler 200 mcg/dose Metered Inhalation Powder</td><td>0.34USD</td><td>dose</td></tr><tr><td>Pulmicort Nebuamp 0.125 mg/ml Suspension</td><td>0.23USD</td><td>ml</td></tr><tr><td>Pulmicort Turbuhaler 100 mcg/dose Metered Inhalation Powder</td><td>0.17USD</td><td>dose</td></tr><tr><td>Rhinocort Turbuhaler 100 mcg/dose Metered Dose Aerosol</td><td>0.13USD</td><td>dose</td></tr><tr><td>Mylan-Budesonide Aq 100 mcg/dose Metered Dose Spray</td><td>0.1USD</td><td>dose</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6598603</td><td>1999-06-23</td><td>2019-06-23</td></tr><tr><td>United States</td><td>6423340</td><td>1993-11-15</td><td>2010-11-15</td></tr><tr><td>Canada</td><td>2071518</td><td>2002-11-12</td><td>2010-11-15</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>226&#176;C</td><td>PhysProp</td></tr><tr><td>water solubility</td><td>insoluble</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>1.9</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>4.57e-02 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.42</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.73</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>13.74</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>-2.9</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>6</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>93.06</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>116.11</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>47.11</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Peter Gruber, Hans Joachim Lach, Norbert Otterbeck, &#8220;Budesonide pellets with a controlled released pattern and process for producing the same.&#8221; U.S. Patent US5932249, issued May, 1991.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=5932249&amp;tbm=pts" target="_blank">US5932249 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00246" target="_blank">D00246 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=3207" target="_blank">3207 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1370" target="_blank">CHEMBL1370 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000320" target="_blank">DAP000320 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA448681" target="_blank">PA448681 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2241003" target="_blank">2241003 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/entocort.htm" target="_blank">http://www.rxlist.com/cgi/generic/entocort.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/budesonide-spray.html" target="_blank">http://www.drugs.com/cdi/budesonide-spray.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cx1621.shtml" target="_blank">http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cx1621.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Budesonide" target="_blank">Budesonide <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>A07EA06<ul class="atc-drug-tree"><li><a href="/atc/A#A">A &#8212; ALIMENTARY TRACT AND METABOLISM</a></li><li><a href="/atc/A07#A07">A07 &#8212; ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS</a></li><li><a href="/atc/A07E#A07E">A07E &#8212; INTESTINAL ANTIINFLAMMATORY AGENTS</a></li><li><a href="/atc/A07EA#A07EA">A07EA &#8212; Corticosteroids acting locally</a></li></ul>D07AC09<ul class="atc-drug-tree"><li><a href="/atc/D#D">D &#8212; DERMATOLOGICALS</a></li><li><a href="/atc/D07#D07">D07 &#8212; CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS</a></li><li><a href="/atc/D07A#D07A">D07A &#8212; CORTICOSTEROIDS, PLAIN</a></li><li><a href="/atc/D07AC#D07AC">D07AC &#8212; Corticosteroids, potent (group III)</a></li></ul>R01AD05<ul class="atc-drug-tree"><li><a href="/atc/R#R">R &#8212; RESPIRATORY SYSTEM</a></li><li><a href="/atc/R01#R01">R01 &#8212; NASAL PREPARATIONS</a></li><li><a href="/atc/R01A#R01A">R01A &#8212; DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE</a></li><li><a href="/atc/R01AD#R01AD">R01AD &#8212; Corticosteroids</a></li></ul>R03BA02<ul class="atc-drug-tree"><li><a href="/atc/R#R">R &#8212; RESPIRATORY SYSTEM</a></li><li><a href="/atc/R03#R03">R03 &#8212; DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</a></li><li><a href="/atc/R03B#R03B">R03B &#8212; OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS</a></li><li><a href="/atc/R03BA#R03BA">R03BA &#8212; Glucocorticoids</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>52:08.08</li>
<li>68:04.00</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB01222.pdf?1265922796">show</a>(52.3 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB01222.pdf?1265922736">show</a>(73.7 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01128">Bicalutamide</a></td><td>CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of budesonide. The clinical significance of this interaction is greater for oral budesonide than for orally inhaled budesonide. Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.</td></tr><tr><td><a href="/drugs/DB00257">Clotrimazole</a></td><td>CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a moderate CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess. </td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). onsider reducing the oral budesonide dose when used together with a strong CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a strong CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess. </td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may increase levels/effect of budesonide.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole may increase levels/effect of budesonide.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Budesonide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Budesonide if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir may increase the plasma concentration of Budesonide. Monitor for toxic Budesonide effects during concomitant administration. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of budesonide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of budesonide if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>A mean delay in time to peak concentration of 2.5 hours is observed with the intake of a high-fat meal, with no significant differences in AUC.</li></ul></td></tr></tbody></table>